2,4-diamino pyrimidine compounds having anti-cell proliferative activity
    4.
    发明授权
    2,4-diamino pyrimidine compounds having anti-cell proliferative activity 失效
    具有抗细胞增殖活性的2,4-二氨基嘧啶化合物

    公开(公告)号:US07176212B2

    公开(公告)日:2007-02-13

    申请号:US10771118

    申请日:2004-02-04

    CPC分类号: C07D239/48

    摘要: A pyrimidine derivative of formula (I) wherein, for example, R1 is hydrogen, (1–6C)alkyl, (3–5C)alkenyl or (3–5C)alkynyl; Q1 and Q2 are independently selected from phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl; and one or both of Q1 and Q2 bears on any available carbon atom one substituent of formula (Ia) [provided that when present in Q1 the substituent of formula (Ia) is not adjacent to the —NH— link]; wherein, for example, X is CH2, O, S or NH; Y is H or as defined for Z; Z is OH, SH, NH2, (1–4C)alkoxy, (1–4C)alkylthio, —NH(1–C)alkyl, —N[(1–4C)alkyl]2 or —NH—(3–8C)cycloalkyl; n is 1, 2 or 3; m is 1, 2 or 3; and Q1 and Q2 may optionally bear other substituents selected, for example, from halogeno, (1–6C)alkyl, cyano and (2–4C)alkenyl; or a pharmaceutically-acceptable salt or in-vivo-hydrolyzable ester thereof; are useful as anti-cancer agents; and processes for heir manufacture and pharmaceutical compositions containing them are described

    摘要翻译: 式(I)的嘧啶衍生物,其中例如R 1是氢,(1-6C)烷基,(3-5C)烯基或(3-5C)炔基; Q 1和Q 2个独立地选自苯基,萘基,茚满基和1,2,3,4-四氢萘基; 并且Q 1和Q 2中的一个或两个在任何可用的碳原子上具有式(Ia)的一个取代基[条件是当存在于Q 1中时, 式(Ia)的取代基不与-NH-连接相邻]; 其中,例如,X是CH 2,O,S或NH; Y为H或Z定义; Z是OH,SH,NH 2,(1-4C)烷氧基,(1-4C)烷硫基,-NH(1-C)烷基,-N [(1-4C)烷基] 或-NH-(3-8C)环烷基; n为1,2或3; m为1,2或3; 且Q 1和Q 2可任选地具有其它取代基,例如选自卤代,(1-6C)烷基,氰基和(2-4C)烯基; 或其药学上可接受的盐或体内可水解的酯; 可用作抗癌剂; 并描述了继承人制造的方法和含有它们的药物组合物

    Pyrimidine compounds
    6.
    发明授权
    Pyrimidine compounds 失效
    嘧啶化合物

    公开(公告)号:US06632820B1

    公开(公告)日:2003-10-14

    申请号:US09763681

    申请日:2001-02-26

    IPC分类号: C07D23948

    CPC分类号: C07D239/48

    摘要: A pyrimidine derivative of formula (I) wherein, for example, R1 is-(1-6C)alkyl or (3-5C)alkenyl [optionally substituted by a phenyl substituent]; Q1 and Q2 are independently selected from phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl; and one or both of Q1 and Q2 bears one substituent of formula (Ia) [provided that when present in Q1 the substituent of formula (Ia) is not adjacent to the —NH-link]; wherein, for example, X is CH2, O, S or NH; Y is H or as defined for Z; Z is OH, SH, NH2, (1-4C)alkoxy, (1-4C)alkylthio, —NH(1-4C)alkyl, —N[(1-4C)alkyl]2 or —NH-(3-8C)cycloalkyl; n is 1, 2 or 3; m is 1, 2 or 3; and Q1 and Q2 may each optionally bear other substituents selected from halogeno, (1-6C)alkyl, cyano and (2-4C)alkenyl, or a pharmaceutically-acceptable salt, or in-vivo-hydrolysable ester thereof; are useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

    摘要翻译: 式(I)的嘧啶衍生物,其中例如R 1为 - (1-6C)烷基或(3-5C)烯基[任选被 苯基取代基]; Q 1 和Q 2 独立地选自苯基,萘基,茚满基和1,2,3,4-四氢萘基 ; 并且Q 1 和Q 2 中的一个或两个具有式(Ia)的一个取代基[条件是当存在于 式(Ia)的取代基不与-NH-连接相邻]。 其中,例如,X是CH 2,O,S或NH; Y为H或Z定义; Z是OH,SH,NH,(1-4C)烷氧基,(1-4C)烷硫基,-NH(1-4C)烷基,-N [(1 -4C)烷基]环烷基或-NH-(3-8C)环烷基; n为1,2或3; m为1,2或3; 并且Q 1 和Q 2 可以各自任选地具有选自卤代,(1-6C)烷基,氰基 和(2-4C)烯基,或其药学上可接受的盐或其体内可水解的酯; 可用作抗癌剂; 并描述了其制造方法和含有它们的药物组合物。